27 Mar 2023 Avacta to present pre-clinical data on AVA3996 at the American Association for Cancer Research Annual Meeting Investors | Therapeutics
17 Jan 2023 Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study Investors | Therapeutics
19 Dec 2022 Avacta to Host Therapeutics Division Science Day on 23rd February 2023 Investors | Therapeutics
05 Sep 2022 AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration Investors | Therapeutics
01 Sep 2022 Phase I clinical study of AVA6000 to advance to the fourth cohort Investors | Therapeutics